Brief: Leap Therapeutics Enrolls First Patient In Part C Of Phase 2 Distinguish Study Of Dkn-01 In Combination With Tislelizumab For The Treatment Of Gastric Or Gastroesophageal Junction Cancer
12/10/2022 12:26
Oct 12 (Reuters) - Leap Therapeutics Inc LPTX.O :
* LEAP THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PART
C OF
PHASE 2 DISTINGUISH STUDY OF DKN-01 IN COMBINATION WITH
TISLELIZUMAB FOR THE TREATMENT OF GASTRIC OR GASTROESOPHAGEAL
JUNCTION CANCER
Source text for Eikon: ID:nPn5LRHRta
Further company coverage: LPTX.O
Recent news on Cypherpunk Technologies
See all newsCypherpunk Technologies Inc reports results for the quarter ended June 30 - Earnings Summary
Cypherpunk Technologies swings to Q2 profit on Zcash gains
Cypherpunk Technologies Inc expected to post a loss of 3 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia